Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PHV03 is a recombinant viral vector vaccine candidate developed by Public Health Vaccines for the prevention of Sudan ebolavirus infection. The vaccine utilizes a recombinant vesicular stomatitis virus (rVSV) platform, specifically the rVSV∆G-SUDV GP construct, where the native VSV glycoprotein (G) is deleted and replaced with the glycoprotein (GP) of the Sudan ebolavirus. This design allows the attenuated virus to express the SUDV GP antigen, thereby stimulating a robust and protective immune response against the Sudan ebolavirus. PHV03 is currently in the preclinical stage of development and is part of a broader pipeline of rVSV-based vaccines targeting viral hemorrhagic fevers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PHV03.